ES2201105T3 - Derivados del bencimidazol con actividad dopaminergica. - Google Patents

Derivados del bencimidazol con actividad dopaminergica.

Info

Publication number
ES2201105T3
ES2201105T3 ES95917441T ES95917441T ES2201105T3 ES 2201105 T3 ES2201105 T3 ES 2201105T3 ES 95917441 T ES95917441 T ES 95917441T ES 95917441 T ES95917441 T ES 95917441T ES 2201105 T3 ES2201105 T3 ES 2201105T3
Authority
ES
Spain
Prior art keywords
alterations
piperazin
benzoimidazol
propan
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95917441T
Other languages
English (en)
Spanish (es)
Inventor
William S. Faraci
Anton F. J. Fliri
Brian T. O'neill
Mark A. Sanner
Stevin H. Zorn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PFIZER
Pfizer Inc
Original Assignee
PFIZER
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PFIZER, Pfizer Inc filed Critical PFIZER
Application granted granted Critical
Publication of ES2201105T3 publication Critical patent/ES2201105T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
ES95917441T 1994-08-05 1995-05-18 Derivados del bencimidazol con actividad dopaminergica. Expired - Lifetime ES2201105T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US28657694A 1994-08-05 1994-08-05
US286576 1994-08-05
US29800594A 1994-08-30 1994-08-30
US298005 1994-08-30

Publications (1)

Publication Number Publication Date
ES2201105T3 true ES2201105T3 (es) 2004-03-16

Family

ID=26963924

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95917441T Expired - Lifetime ES2201105T3 (es) 1994-08-05 1995-05-18 Derivados del bencimidazol con actividad dopaminergica.

Country Status (20)

Country Link
EP (1) EP0775118B1 (enExample)
JP (1) JP3004727B2 (enExample)
KR (1) KR970704698A (enExample)
AT (1) ATE242220T1 (enExample)
AU (1) AU703431B2 (enExample)
BR (1) BR9503572A (enExample)
CA (1) CA2196769C (enExample)
CO (1) CO4410330A1 (enExample)
DE (1) DE69530988T2 (enExample)
DK (1) DK0775118T3 (enExample)
ES (1) ES2201105T3 (enExample)
FI (1) FI970469A7 (enExample)
IL (1) IL114754A0 (enExample)
MX (1) MX9700959A (enExample)
NZ (1) NZ284851A (enExample)
PE (1) PE35796A1 (enExample)
PT (1) PT775118E (enExample)
TR (1) TR199500956A2 (enExample)
TW (1) TW306920B (enExample)
WO (1) WO1996004250A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3204456B2 (ja) * 1995-12-21 2001-09-04 ファイザー・インコーポレーテッド ２，７―置換オクタヒドロ―ピロロ［１，２―ａ］ピラジン誘導体
EP0953567A3 (en) 1998-04-29 2003-04-02 Pfizer Products Inc. Bicyclic substituted piperazine-, piperidine- and tetrahydropyridine derivatives, their preparation and their use as agents with central dopaminergic (dopamine D4 receptor) activity
DE60009154D1 (de) * 1999-12-30 2004-04-22 Lundbeck & Co As H Phenylpiperazinyl-derivate
EP1177792A3 (en) * 2000-07-27 2002-10-23 Pfizer Products Inc. Dopamine D4 Ligands for the treatment of novelty-seeking disorders
AU2689502A (en) * 2000-11-22 2002-06-03 Abbott Lab The use of selective dopamine d4 receptor agonists for treating sexual dysfunction
US7432304B2 (en) 2001-05-30 2008-10-07 The Regents Of The University Of Michigan Small molecule antagonists of Bcl-2 family proteins
EP1406631A4 (en) * 2001-06-13 2005-03-23 Univ Michigan DOPAMIN RECEPTOR LIGANDS AND THERAPEUTIC METHODS BASED THEREFOR
US7354928B2 (en) 2001-11-01 2008-04-08 The Regents Of The University Of Michigan Small molecule inhibitors targeted at Bcl-2
CN101492383A (zh) * 2002-03-12 2009-07-29 惠氏公司 制备手性1,4-二取代哌嗪的方法
JP2004123562A (ja) * 2002-09-30 2004-04-22 Japan Science & Technology Corp 神経細胞死抑制作用を有する化合物を用いた医薬
EP1719761A4 (en) * 2004-02-23 2007-10-10 Dainippon Sumitomo Pharma Co NEW HETEROCYCLIC CONNECTION
CA2561303C (en) 2004-03-25 2011-01-18 The Regents Of The University Of Michigan Gossypol co-crystals and the use thereof
EP1634598A1 (en) * 2004-09-07 2006-03-15 Laboratorios Del Dr. Esteve, S.A. Use of piperazine derivatives and analogues for the manufacture of a medicament for the prophylaxis and/or treatment of disorders of food ingestion
JP6350535B2 (ja) * 2012-11-26 2018-07-04 シェンヤン ハイワン バイオテクノロジー カンパニー リミテッドＳｈｅｎｙａｎｇ Ｈａｉｗａｎｇ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ Ｃｏ．，Ｌｔｄ 含窒素ベンゾ複素五員環含窒素ベンゾ複素五員環ピペラジン又はピペリジン誘導体の用途
JP2016500084A (ja) * 2012-11-26 2016-01-07 リアオニン エミー バイオロジカル ファーマシューティカル カンパニー リミテッドＬｉａｏｎｉｎｇ Ｅｍｍｙ Ｂｉｏｌｏｇｉｃａｌ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．，Ｌｔｄ 含窒素ベンゾ複素五員環基ピペリジン又はピペラジン誘導体及びその作製方法並びに薬剤組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3647790A (en) * 1969-04-08 1972-03-07 American Home Prod Ouinoxalinyl-oxazolidines and -oxazines
FR2579596B1 (fr) * 1985-03-26 1987-11-20 Inst Nat Sante Rech Med (imidazolyl-4) piperidines, leur preparation et leur application en therapeutique
IT1251144B (it) * 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone

Also Published As

Publication number Publication date
FI970469A0 (fi) 1997-02-04
FI970469L (fi) 1997-04-04
KR970704698A (ko) 1997-09-06
JP3004727B2 (ja) 2000-01-31
DE69530988T2 (de) 2003-12-04
FI970469A7 (fi) 1997-04-04
TW306920B (enExample) 1997-06-01
DK0775118T3 (da) 2003-09-29
WO1996004250A1 (en) 1996-02-15
EP0775118B1 (en) 2003-06-04
AU2351095A (en) 1996-03-04
NZ284851A (en) 1998-07-28
TR199500956A2 (tr) 1996-07-21
PT775118E (pt) 2003-10-31
BR9503572A (pt) 1996-04-30
JPH09510706A (ja) 1997-10-28
MX9700959A (es) 1997-05-31
CA2196769C (en) 2002-10-08
CA2196769A1 (en) 1996-02-15
DE69530988D1 (de) 2003-07-10
ATE242220T1 (de) 2003-06-15
EP0775118A1 (en) 1997-05-28
IL114754A0 (en) 1995-11-27
CO4410330A1 (es) 1997-01-09
AU703431B2 (en) 1999-03-25
PE35796A1 (es) 1996-10-01

Similar Documents

Publication Publication Date Title
US11858900B2 (en) Fluorinated 2-amino-4-(substituted amino)phenyl carbamate derivatives
CA2178161C (en) Indole derivatives
US6949574B2 (en) (Oxime)carbamoyl fatty acid amide hydrolase inhibitors
JPH11512701A (ja) 選択的なβ▲下３▼アドレナリン作動性アゴニスト
EP0775118B1 (en) Benzimidazole derivatives having dopaminergic activity
ES2253782T3 (es) Antagonistas de receptor de bombesina no peptidicos.
US7442693B2 (en) Diazepine compounds as ligands of the melanocortin 1 and/or 4 receptors
JP2010024243A (ja) 緑内障および近視を処置するためのベンゾ［ｇ］キノリン誘導体
US4517188A (en) 1-Pyrimidinyloxy-3-hetaryl-alkylamino-2-propanols
JPH037264A (ja) ヒスタミン誘導体及びその製造方法並びに該誘導体を含有する医薬
JPH10513443A (ja) ５ＨＴ▲下２ｃ▼レセプターアンタゴニスト活性を有する複素環化合物
KR100530208B1 (ko) 벤지미다졸 유도체
KR19990076616A (ko) 2,7-치환된 옥타하이드로-피롤로[1,2-에이]피라진 유도체
JP2000290240A (ja) 生物学的に活性なアミンの中間体
US5889010A (en) Benzimidazole derivatives having dopaminergic activity
FR2477150A1 (fr) Nouveaux derives heterocycliques, procedes pour leur preparation et compositions pharmaceutiques les comportant
US20040142850A1 (en) Benzimidazolidinone derivatives
US6232337B1 (en) Selective β3 adrenergic agonists
US5212173A (en) Alkylaminoalkylamine and ether compounds, processes and intermediates for their preparation, and medicaments containing them
JPH0314562A (ja) 新規なアルキレンジアミン誘導体およびグルタミン酸遮断剤
FR2639944A1 (fr) Nouveaux derives de l'indole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CH620678A5 (en) Process for the preparation of a derivative of piperidine
EP0153746B1 (en) 3-amino-2-hydroxypropyl derivatives of pyrimidin-4-one
US20100105749A1 (en) Chemical compounds, pharmaceutical compositions and methods
JPS5838238A (ja) 新規な化合物およびその製法